Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2006, Circulation, 114, e84, 10.1161/CIRCULATIONAHA.106.176857 Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 Lip, 2010, Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting, Thromb Haemost, 103, 13, 10.1160/TH09-08-0580 Hansen, 2010, Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation, Arch Intern Med, 170, 1433, 10.1001/archinternmed.2010.271 Smith, 2006, Circulation, 113, 156, 10.1161/CIRCULATIONAHA.105.170815 Karjalainen, 2007, Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting, Eur Heart J, 28, 726, 10.1093/eurheartj/ehl488 Orford, 2004, Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patient with an indication for anticoagulation, Am Heart J, 147, 463, 10.1016/j.ahj.2003.06.004 Doyle, 2009, Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice, J Am Coll Cardiol, 53, 2019, 10.1016/j.jacc.2008.12.073 Roldán, 2008, Contra: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions’. Not for everybody, Thromb Haemost, 100, 754, 10.1160/TH08-06-0363 Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4 Lip, 2008, Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention, BMJ, 337, a840, 10.1136/bmj.39533.570602.BE Ruiz-Nodar, 2008, Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis, J Am Coll Cardiol, 51, 818, 10.1016/j.jacc.2007.11.035 Leon, 1998, A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators, N Engl J Med, 339, 1665, 10.1056/NEJM199812033392303 Rubboli, 2005, Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting, Cardiology, 104, 101, 10.1159/000086918 Urban, 1998, Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS), Circulation, 98, 2126, 10.1161/01.CIR.98.20.2126 Van Es, 2002, Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial, Lancet, 360, 109, 10.1016/S0140-6736(02)09409-6 Hurlen, 2002, Warfarin, aspirin, or both after myocardial infarction, N Engl J Med, 347, 969, 10.1056/NEJMoa020496 Dewilde, 2009, Trial design: WOEST trial: design and rationale of the WOEST trial: what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting, Am Heart J, 158, 713, 10.1016/j.ahj.2009.09.001 Silber, 2005, Guidelines for percutaneous coronary interventions, Eur Heart J, 26, 804, 10.1093/eurheartj/ehi564 Patel, 2009, Circulation, 119, 1330, 10.1161/CIRCULATIONAHA.108.191768 Thygesen, 2007, Universal definition of myocardial infarction, Eur Heart J, 28, 2525, 10.1093/eurheartj/ehm355 Chesebro, 1987, Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge, Circulation, 76, 142, 10.1161/01.CIR.76.1.142 1993, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, N Engl J Med, 329, 673, 10.1056/NEJM199309023291001 Mehran, 2011, Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation, 123, 2736, 10.1161/CIRCULATIONAHA.110.009449 Cutlip, 2007, Clinical endpoints in coronary stent trials: a case for standardized definitions, Circulation, 115, 2344, 10.1161/CIRCULATIONAHA.106.685313 Steg, 2011, Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology, Eur Heart J, 32, 1854, 10.1093/eurheartj/ehr204 Roy, 2008, Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation, Am J Cardiol, 102, 1614, 10.1016/j.amjcard.2008.07.063 Lip, 2011, Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis, Thromb Haemost, 106, 997, 10.1160/TH11-10-0690 Kukreja, 2009, Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients, Am J Cardiol, 103, 203, 10.1016/j.amjcard.2008.08.068 Faxon, 2011, Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective, Thromb Haemost, 106, 572, 10.1160/TH11-04-0262 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Berger, 2010, Circulation, 121, 2575, 10.1161/CIRCULATIONAHA.109.895342 Park, 2010, Duration of dual antiplatelet therapy after implantation of drug-eluting stents, N Engl J Med, 362, 1374, 10.1056/NEJMoa1001266 Gwon, 2012, Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study, Circulation, 125, 505, 10.1161/CIRCULATIONAHA.111.059022 Valgimigli, 2012, Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial, Circulation, 125, 2015, 10.1161/CIRCULATIONAHA.111.071589 Miller, 2012, Meta-Analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation, Am J Cardiol, 110, 453, 10.1016/j.amjcard.2012.03.049 Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327 Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4